Senior Director of Medical Affairs Presents at the 17th World Congress of Cancers on the Skin in Sydney, Australia

Senior Director of Medical Affairs Presents at the 17th World Congress of Cancers on the Skin in Sydney, Australia

Senior Director of Medical Affairs Presents at the 17th World Congress of Cancers on the Skin in Sydney, Australia

Sydney, Australia – Aug 18, 2018 – At the 17th World Congress of Cancers on the Skin (WCCS) in Sydney, Australia, Dr. Michael Bonning presented on the “Novel Use Of An Adjunctive Skin Cancer Assessment Tool Utilising Elastic Scattering Spectroscopy And Machine Learning.”

According to the World Health Organization, up to 3 million non-melanoma skin cancers and 132,000 melanomas occur each year globally. 2 in 3 Australians, and 1 in 5 Americans, develop skin cancer in their lifetimes. This year, WCCS is co-sponsored by The Skin and Cancer Foundation Australia and The Skin Cancer Foundation, New York as an effort to combat skin cancer globally. This conference was attended by over 550 general practitioners, physicians, dermatologists, oncologists, surgeons, and pathologists.

Dr. Michael Bonning described Elastic Scattering Spectroscopy (ESS), a specific form of sub-diffuse reflectance spectroscopy, as a method to observe disease-associated changes at a cellular and subcellular level. There is clinical evidence that ESS can assess malignancy in multiple tissue types. Dr. Bonning presented on an investigator-blinded multi-center study where patients with skin lesions were evaluated and had ESS measurements taken to assess the lesion.

Dr. Bonning stated, “as value-based health interventions drive changes to healthcare delivery strategies, the value of effective lesion triage will likely increase in importance.”

Dr. Michael Bonning, Senior Director of Medical Affairs at DermaSensor, is an Australian board certified family practitioner with an extensive background of advising government, non-profits and lobby bodies. He has spent four years as a director of the largest primary health care residency program in Australia. Michael is an adjunct fellow at Macquarie University and takes a public health approach to skin cancer management and the value of early identification and management.

 

About the Company:

DermaSensor, a Miami-based digital health company, is a connected device company that enables healthcare professionals to efficiently check for skin cancer by leveraging cutting-edge technologies. DermaSensor has developed an affordable handheld tool that uses artificial intelligence and spectroscopy to evaluate skin lesions for potential skin cancer in a matter of seconds. By enabling quick and effective skin cancer checks, DermaSensor hopes to ultimately improve patient outcomes. To learn more, visit www.dermasensor.com.

 

Media Contact
Palak Bhatnagar
contact@dermasensor.com
415-322-0838